These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 9067410

  • 1. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T, Ueki T, Sasaki Y, Kajiwara T, Li B, Moriyama N, Kawabe K.
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [Abstract] [Full Text] [Related]

  • 2. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H, Matsumoto A, Kitamura T, Takeuchi T.
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T, Konno-Takahashi N, Kasuya Y, Ogushi T, Nishimatsu H, Kitamura T.
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M.
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [Abstract] [Full Text] [Related]

  • 5. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
    Ali SA, Rees RC, Anderson DQ, Reed MW, Goepel JR, Brown NJ.
    Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
    [Abstract] [Full Text] [Related]

  • 6. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
    Nishimatsu H, Takeuchi T, Ueki T, Kajiwara T, Moriyama N, Ishida T, Li B, Kakizoe T, Kitamura T.
    Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
    [Abstract] [Full Text] [Related]

  • 7. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
    Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, Borden EC, Yi T.
    J Immunol; 2005 Nov 15; 175(10):7003-8. PubMed ID: 16272361
    [Abstract] [Full Text] [Related]

  • 8. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
    Harada M, Iida Y, Kotani H, Minami T, Komohara Y, Eto M, Yoshikawa K, Uemura H.
    Cancer Immunol Immunother; 2022 Feb 15; 71(2):339-352. PubMed ID: 34160685
    [Abstract] [Full Text] [Related]

  • 9. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
    Han KH, Kim KW, Yan JJ, Lee JG, Lee EM, Han M, Cho EJ, Kang SS, Lim HJ, Koo TY, Ahn C, Yang J.
    BMC Urol; 2016 Jan 16; 16():2. PubMed ID: 26772545
    [Abstract] [Full Text] [Related]

  • 10. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K.
    J Immunother; 2010 Apr 16; 33(3):236-49. PubMed ID: 20445344
    [Abstract] [Full Text] [Related]

  • 11. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
    Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE.
    Cancer Gene Ther; 1998 Apr 16; 5(5):321-30. PubMed ID: 9824052
    [Abstract] [Full Text] [Related]

  • 12. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.
    Hara I, Hotta H, Sato N, Eto H, Arakawa S, Kamidono S.
    Jpn J Cancer Res; 1996 Jul 16; 87(7):724-9. PubMed ID: 8698622
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, Kurimoto M, Gohji K, Arakawa S, Ichihashi M, Kamidono S.
    Cancer Gene Ther; 2000 Jan 16; 7(1):83-90. PubMed ID: 10678360
    [Abstract] [Full Text] [Related]

  • 15. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM, Dams-Kozlowska H, Kazimierczak U, Wysocki PJ, Mackiewicz A.
    Expert Opin Biol Ther; 2011 Dec 16; 11(12):1555-67. PubMed ID: 21995459
    [Abstract] [Full Text] [Related]

  • 16. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
    Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M.
    Cancer Immunol Immunother; 2007 Sep 16; 56(9):1417-28. PubMed ID: 17285290
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
    Mendiratta SK, Quezada A, Matar M, Wang J, Hebel HL, Long S, Nordstrom JL, Pericle F.
    Gene Ther; 1999 May 16; 6(5):833-9. PubMed ID: 10505108
    [Abstract] [Full Text] [Related]

  • 19. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
    J Immunol; 2002 Apr 01; 168(7):3484-92. PubMed ID: 11907109
    [Abstract] [Full Text] [Related]

  • 20. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
    Marumo K, Oya M, Murai M, Tazaki H.
    Int J Urol; 1996 Jan 01; 3(1 Suppl):S24-7. PubMed ID: 24304015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.